Generic Medicine Info
Indications and Dosage
Ocular hypertension, Open-angle glaucoma
Adult: As 1% solution: Instill 1 drop in the affected eye(s) bid.

Adult: 2.5-30 mg/day, adjusted according to response.

Angina pectoris, Cardiac arrhythmias
Adult: 2.5-30 mg/day, adjusted according to response.
Renal Impairment
CrCl Dosage
<30 Not recommended.
30-80 10 mg/day.
Should be taken with food.
AV block (2nd and 3rd degree), sinus bradycardia, sino-atrial block, sick sinus syndrome, overt cardiac failure, cardiogenic shock. Bronchospasm, bronchial asthma, severe COPD, pulmonary oedema.
Special Precautions
Patients w/ 1st degree AV block, Raynaud's disease, untreated phaeochromocytoma, COPD, DM, myasthenia gravis. May mask symptoms of hyperthyroidism and hypoglycaemia. Abrupt withdrawal may precipitate a thyroid storm. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Bradycardia, hypotension, heart failure. GI and taste disturbances, headache, dizziness, insomnia and sinusitis, localized and generalized rash, pruritus. Ocular irritation (e.g. itching, tearing, redness), photophobia, blurred vision.
Symptoms: Dizziness, headache, shortness of breath, symptomatic bradycardia, hypotension, bronchospasm, and acute cardiac failure. Management: Symptomatic and supportive treatment. In case of ocular overdose, the eyes should be flushed w/ water or saline soln.
Drug Interactions
Coadministration w/ catecholamine-depleting drugs (e.g. reserpine), Ca channel blockers, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics may cause additive effects e.g. hypotension and/or marked bradycardia. Mydriasis may occur w/ concomitant epinephrine.
Description: Carteolol is a non-cardioselective β-blocker w/ intrinsic sympathomimetic activity. It decreases aqueous humour production which causes intraocular pressure reduction.
Absorption: Well absorbed from the GI tract. Bioavailability: Approx 84%. Time to peak plasma concentration: 1-4 hr.
Distribution: Plasma protein binding: Approx 20-30%.
Metabolism: Undergoes CYP2D6-mediated 8-hydroxylation to its active metabolite (8-hydroxycarteolol), and glucuronic acid conjugates of carteolol and 8-hydroxycarteolol.
Excretion: Via urine: Approx 50-70% (as unchanged drug). Plasma half-life: 3-6 hr.
Store between 15-25°C. Protect from light.
MIMS Class
Antiglaucoma Preparations / Beta-Blockers
Anon. Carteolol (Ophthalmic): Drug information. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 25/11/2013.

Buckingham R (ed). Carteolol Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 25/11/2013.

Carteolol Hydrochloride Solution (Alcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 25/11/2013.

Wickersham RM. Carteolol Hydrochloride. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. Accessed 25/11/2013.

Disclaimer: This information is independently developed by MIMS based on Carteolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in